|
FAQ
Detailed Search
|
| Topic: |
diabetes (dm) |
| Title: |
New Agents for the Treatment of Diabetes. |
| Author: |
Chirico, M.; et al |
| Source: |
Review of Endocrinology. 1(2): 42-46. June 2007. |
| Abstract: |
This article reviews new delivery methods for insulin and new agents for the treatment of diabetes, notably those based on the incretin phenomenon. The authors describe inhaled human insulin; pramlintide, which is an injectable synthetic analog of amylin; the incretin effect, which explains up to 60 percent of the postprandial insulin secretion of the pancreas; GLP-1 agonists, including exenatide and liraglutide; DPP-4 inhibitors, notably sitagliptin and vildagliptin; and the benefits of using these newer drugs in combination with older antidiabetic agents, particularly in patients with type 2 diabetes. The authors conclude that the GLP-1 receptor agonists and DPP-4 enzyme inhibitors offer comparable HbA1c lowering with few side effects and may also lead to weight loss. 1 figure. 3 tables. 24 references. |
| Format: |
Journal Article |
| Language: |
English. |
| Major Keywords: |
Diabetes Mellitus. Type 2 Diabetes. Drug Therapy. Incretin Mimetics. Insulin. Administration and Dosage. Blood Glucose. |
| Minor Keywords: |
Pramlintide. Exenatide. Sitagliptin. Inhaled Insulin. Incretins. Physiology. Glycosylated Hemoglobin. Drug Effects. Patient Selection. Patient Care Management. |
| Publication Number: |
DMJA13030. |
| Printer-Friendly Version | Return to Search Results |
|
<-- previous record
|
next record -->
|
|
 |
|
